NeuroMed receives second tranche of financing

NeuroMed Technologies has secured second-tranche financing of $8.6 million, as part of a $21-million round announced a year ago. The second tranche was delivered once the Vancouver-based developer of small molecule pain and stroke drugs achieved certain milestones. The new funding will be used to advance development of its paid products and accelerate others in the pipeline. NeuroMed now has seven patents, one notice of allowance and 28 patents pending. Investors in this round include GrowthWorks Capital, MDS Capital, RBC Capital Partners, Trian Equities, Business Development Bank of Canada , Pictet & Cie, Kinetic Capital and several private investors....